-
Thematic Analysis
Genome Editing Drugs Landscape: Comprehensive Analysis of Current Drugs and Dynamics
The Genome Editing Drugs Landscape report delivers a comprehensive analysis of the current and emerging genome editing therapies shaping the pharmaceutical industry. Viewed through the lens of drug development, clinical progress, regulatory evolution, and commercial performance, the report helps stakeholders understand how genome editing technologies are transitioning from experimental platforms to viable therapeutic solutions. By combining clinical pipeline analysis, regulatory developments, and market performance insights, the report highlights the key forces reshaping the genome editing landscape. It enables readers to...
-
Sector Analysis
IDWeek 2025: Pre-Conference Coverage
IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists. In advance of the confernece, GlobalData highlighted highly anticipated and noteworthy abstracts in this Pre-Conference Coverage report.
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, September 2025
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
Diabetic Retinopathy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Diabetic Retinopathy Therapeutics. • In 2024, there were more than 46 million ldiagnosed prevalent cases of DR in the 16 countries covered in GlobalData’s epidemiology forecast. • Currently, the DR market is saturated with generic drugs, and the platelet activating factor (PAF) inhibitor drug class dominates the approved innovator drugs currently available to treat DR. • The DR pipeline holds 140 molecules, with three assets in...
-
Analyst Opinions
Industrial Robots: Trends and Innovations
Industrial Robots move from automation to autonomy Industrial robotics is entering a new phase of transformation as intelligent, mobile, and humanoid systems reshape automation across sectors. Evolving beyond traditional caged robots, next-generation platforms integrate AI, computer vision, digital twins, and advanced actuation to enable adaptive, flexible, and connected operations. Automotive, electronics, and aerospace remain core adopters, while healthcare, construction, and logistics are emerging growth frontiers. Companies such as BMW, Mercedes-Benz, and Tesla are piloting humanoids for assembly and logistics, ABB,...
-
Sector Analysis
Huntington’s Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034
This report covers the 7MM and provides an Excel-based forecast model for the Huntington’s Disease market through 2034. The current HD treatments are used to alleviate the symptoms associated with the disease, with all of the approved drugs indicated for the management of chorea associated with HD. VMAT2 inhibitors dominated the HD market in 2024, accounting for 99.8% of sales in the 7MM. The key focus in the pipeline is on developing DMTs for HD, and huntingtin-lowering strategies are key...
-
Thematic Analysis
China's Evolution in Global Drug Development and Clinical Trials: Strategic Intelligence
In 2015, China’s state council launched ‘Opinions on Deepening the Reform of the Review and Approval Processes to Encourage Innovation of Drugs and Medical Devices,’ which was the catalyst of change to implement several regulatory frameworks to encourage domestic innovation, expedite drug approvals, and enhance China’s presence on the global pharmaceutical stage. The US has the largest share of global drugs in development at 40%, China has 20%, and the 5EU (France, Germany, Italy, Spain, and the UK) has 11%...
-
Thematic Analysis
China's Licensing Trends Shaping Global Drug Development: Strategic Intelligence
Over the past five years, China’s biotech sector’s out-licensing deals have increased significantly. Between 2020 and 2024, the compound annual growth rate (CAGR) was approximately 21.7% for licensing agreements, which is a significant increase highlighting the strength of innovative drugs coming from China. This can be attributed to accelerated regulatory reforms, resulting in streamlined drug approvals and extended market exclusivity. Oncology accounted for 59% of these deals and made up 52% of the total deal value during this time period....
-
Sector Analysis
European Association for the Study of Diabetes (EASD): 2025 Annual Meeting Highlights
The European Association for the Study of Diabetes (EASD) is a leading academic, non-profit organization dedicated to advancing research, education, and care in the field of diabetes mellitus. Founded in 1965 and headquartered in Düsseldorf, Germany, EASD brings together scientists, clinicians, nurses, allied health professionals, and students from around the world who are interested in diabetes research and its clinical application. EASD 2025 took place in Vienna, Austria, between 15-19 September 2025. GlobalData's infectious diseases team attended industry-sponsored and scientific sessions...
-
Sector Analysis
Industry Scores a Win as Watered-Down Version of Canada’s IRP Reform Unveiled in Final Guidelines, but Prices Will Nevertheless Decline
Shortly after the release of Canada's long-awaited final guidelines for the implementation of its International Reference Pricing (IRP) system reform, GlobalData reflects on how the final reform compares to the original plans and where the real danger to the pharma industry lies as the new rules take effect.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.